Pfizer reorganises
Pharmaceutical giant Pfizer is reorganising its company into three businesses to help the company “achieve its growth potential”.
A science-based Innovative Medicines business will now include biosimilars and a new hospital business unit for anti-infectives and sterile injectables. These units possess significant therapeutic area expertise in the medical, commercial and patient experience domains and will provide a strong commercialisation platform for these medicines.